[ad_1] AstraZeneca has announced the positive results of DECLARE (Effect Dapagliflozin on cardiovascular events), a cardiovascular effects test (CVOT) of Poshi (name of the ingredient: Dapagliffrozen). The findings are presented in a …
Read More »[메디파나뉴스]FOSHI, DECLARE-TIMI58, Reduces admissions for heart failure or CV death
